Ribocure Pharmaceuticals AB (Ribocure) is a newly formed international R&D center based in Gothenburg and a subsidiary of Suzhou Ribo Life Science Co., Ltd. Ribocure Pharmaceuticals AB represents the parent company´s dedication to globalize oligonucleotide technology and potentially life-saving oligonucleotide therapies. Ribocure Pharmaceuticals AB will be focusing on development of the parent company´s assets and pipeline in ex-China arena as well as new target ideas from academic and non-academic partnership. Specific efforts will be directed to building innovative capacities to conduct clinical trials and developing siRNA drugs for disease indications such as liver, cardiovascular and metabolic diseases, as well as orphan diseases to address real unmet medical needs.
